CORRECTION

Composition of the Nomination Committee of Orion Corporation

ORION CORPORATION STOCK EXCHANGE RELEASE 27 APRIL 2021 at 19.50 EEST

CORRECTION: Composition of the Nomination Committee of Orion Corporation

Orion corrects the stock exchange release on the composition of the Nomination Committee of the Company published on 27 April at 18.20 EEST. In the original stock exchange release the company incorrectly stated that Erkki Etola and Matti Kavetvuo would be members of the Nomination Committee. In addition, Mikael Silvennoinen was missing from the composition of the Nomination Committee. The correct composition of the Nomination Committee and the corrected release as a whole can be found below:

Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:

• Annika Ekman
• Petteri Karttunen
• Timo Maasilta
• Mikael Silvennoinen
• Heikki Westerlund
• Jukka Ylppö

Heikki Westerlund was elected Chairman of the Committee.

The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.

The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at https://www.orion.fi/en/Orion-group/corporate-governance/board-of-dire ... , a page in the Corporate Governance section of the Orion Group internet website.

  
Orion Corporation

Timo Lappalainen President and CEO

Olli Huotari SVP, Corporate Functions

                                                                       
Contact person:
Timo Lappalainen, President and CEO
tel. [phone]

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.